Analyzing CGTX’s price-to-book ratio for the last quarter

In the current trading session, Cognition Therapeutics Inc’s (CGTX) stock is trading at the price of $1.48, a fall of -4.22% over last night’s close. So, the stock is trading at a price that is -25.13% less than its 52-week high of $1.97 and 563.52% better than its 52-week low of $0.22. Based on the past 30-day period, the stock price is -24.62% below the high and +167.33% above the low.

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CGTX’s SMA-200 is $0.5220.

CGTX’s price to book ratio for the most recent quarter was 13.63, resulting in an 9.37 price to cash per share for the period.

How does Cognition Therapeutics Inc (CGTX) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 5 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.60 in simple terms.

Cognition Therapeutics Inc (CGTX): Earnings History

If we examine Cognition Therapeutics Inc’s recent earnings history, in the last quarter ended on 6/30/2025, it posted adjusted earnings per share of -$0.11, beating the consensus of -$0.1. In other words, it beat the consensus by -$0.01, resulting in a -4.76% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2025, the stock recorded adjusted earnings per share of -$0.11 in contrast with the Outlook of -$0.1. That was a difference of -$0.01 and a surprise of -4.76%.

Cognition Therapeutics Inc (CGTX): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 3 different analysts, who are expecting earnings to fall in between the range of -0.06 and -0.09 with an average Earnings Estimate of -0.08 which is in contrast with the last year earnings estimate of -0.25 and also replicates 68.00% growth rate year over year.

Cognition Therapeutics Inc (NASDAQ: CGTX) Ownership Details

I will give a breakdown of the key shareholders in Cognition Therapeutics Inc (CGTX). Recent figures show that the company’s insiders hold 0.85% of shares. A total of 51 institutional investors hold shares in the company, making 15.33% of its stock and 15.46% of its float.

Jun 30, 2025, it was reported that the Company’s largest institutional holder is Bios Capital Management, LP holding total of 6.0 shares that make 8.17% of the company’s total number of shares and are currently priced at 9.15 million.

The securities firm Vanguard Group Inc holds 1.3 shares of CGTX, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 1.78%, and the holding percentage of shares is valued at 1.99 million.

An overview of Cognition Therapeutics Inc’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Cognition Therapeutics Inc (CGTX) traded 8,399,962 shares per day, with a moving average of $0.8989 and price change of +0.7850. With the moving average of $0.6117 and a price change of +1.1949, about 11,069,694 shares changed hands on average over the past 50 days. Finally, CGTX’s 100-day average volume is 6,120,804 shares, alongside a moving average of $0.4848 and a price change of +1.0257.

Hot this week

DGXX’s price-to-free cash flow ratio: What it means for investors

In the current trading session, Digi Power X Inc's...

Should investors be concerned about BLMZ’s high price-to-sales ratio?

Harrison Global Holdings Inc (BLMZ)'s stock is trading at...

IPA’s valuation metrics: A comprehensive analysis

ImmunoPrecise Antibodies Ltd (IPA)'s stock has witnessed a price...

How does FMST’s price to cash per share ratio compare in the market?

Currently, Foremost Clean Energy Ltd's (FMST) stock is trading...

Analyzing NB’s price-to-book ratio for the last quarter

In the current trading session, NioCorp Developments Ltd's (NB)...

Topics

DGXX’s price-to-free cash flow ratio: What it means for investors

In the current trading session, Digi Power X Inc's...

Should investors be concerned about BLMZ’s high price-to-sales ratio?

Harrison Global Holdings Inc (BLMZ)'s stock is trading at...

IPA’s valuation metrics: A comprehensive analysis

ImmunoPrecise Antibodies Ltd (IPA)'s stock has witnessed a price...

How does FMST’s price to cash per share ratio compare in the market?

Currently, Foremost Clean Energy Ltd's (FMST) stock is trading...

Analyzing NB’s price-to-book ratio for the last quarter

In the current trading session, NioCorp Developments Ltd's (NB)...

A closer look at WOLF’s price-to-free cash flow ratio

Wolfspeed Inc (WOLF)'s stock is trading at $1.32 at...

AGL’s price-to-sales ratio: Is it a good investment opportunity?

Agilon Health Inc (AGL)'s stock has witnessed a price...

Understanding ASBP stock ratios for better investment decisions

Currently, Aspire Biopharma Holdings Inc's (ASBP) stock is trading...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.